Sana Biotechnology launches $75 million public stock offering

Sana Biotechnology Inc. (NASDAQ: SANA) announced it has commenced an underwritten public offering of $75 million of common stock and pre-funded warrants. The Seattle-based company, which focuses on engineered cell therapies, also plans to grant underwriters a 30-day option to purchase up to an additional $11.25 million of common stock.

Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities, and TD Cowen are serving as joint book-running managers for the offering. All shares and warrants in the proposed offering will be sold by the company.

The offering is being conducted under a Registration Statement on Form S-3 previously filed with and declared effective by the Securities and Exchange Commission. The company stated the offering is subject to market conditions and completion cannot be assured.

Sana Biotechnology develops engineered cells as medicines for patients and maintains operations in Seattle, Cambridge, Massachusetts, and South San Francisco.

You May Also Be Interested In

• Polyrizon launches $4M registered direct offering and private placement
• Lianhe Sowell prices $11M follow-on stock offering on Nasdaq
• BioHarvest Sciences seeks dual listing on Tel Aviv Stock Exchange